Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Benamran

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Urologic Oncology|October 12, 2020
Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassificationsRomain Diamand, Guillaume Ploussard, Mathieu Roumiguié, et al.
European Urology|October 7, 2020
External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical ProstatectomyRomain Diamand, Guillaume Ploussard, Mathieu Roumiguié, et al.
European Urology Focus|October 9, 2022
Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?Romain Diamand, Simone Albisinni, Jean-Baptiste Roche, et al.
The Prostate|January 27, 2023
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsyRomain Diamand, Alexandre Peltier, Jean-Baptiste Roche, et al.
European Urology Focus|May 5, 2023
A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter StudyGeorges Mjaess, Alexandre Peltier, Jean-Baptiste Roche, et al.
Minerva Urology and Nephrology|October 25, 2022
Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?Michael Baboudjian, Alae Touzani, Alberto Martini, et al.
World Journal of Urology|December 12, 2022
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracyRomain Diamand, Alexandre Peltier, Jean-Baptiste Roche, et al.
European Urology Oncology|October 24, 2022
Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM ClassificationMichael Baboudjian, Bastien Gondran-Tellier, Alae Touzani, et al.
European Urology Focus|September 24, 2022
External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical ProstatectomyRomain Diamand, Jean-Baptiste Roche, Elena Lievore, et al.
The Prostate|October 19, 2022
Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsyMarco Oderda, Simone Albisinni, Daniel Benamran, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Urologic Oncology|October 12, 2020
Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassificationsRomain Diamand, Guillaume Ploussard, Mathieu Roumiguié, et al.
European Urology|October 7, 2020
External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical ProstatectomyRomain Diamand, Guillaume Ploussard, Mathieu Roumiguié, et al.
European Urology Focus|October 9, 2022
Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?Romain Diamand, Simone Albisinni, Jean-Baptiste Roche, et al.
The Prostate|January 27, 2023
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsyRomain Diamand, Alexandre Peltier, Jean-Baptiste Roche, et al.
European Urology Focus|May 5, 2023
A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter StudyGeorges Mjaess, Alexandre Peltier, Jean-Baptiste Roche, et al.
Minerva Urology and Nephrology|October 25, 2022
Oncological outcomes of radical prostatectomy in very high-risk patients according to STAMPEDE criteria: does local treatment alone still have a place in the era of intensified systemic therapies?Michael Baboudjian, Alae Touzani, Alberto Martini, et al.
World Journal of Urology|December 12, 2022
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracyRomain Diamand, Alexandre Peltier, Jean-Baptiste Roche, et al.
European Urology Oncology|October 24, 2022
Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM ClassificationMichael Baboudjian, Bastien Gondran-Tellier, Alae Touzani, et al.
European Urology Focus|September 24, 2022
External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical ProstatectomyRomain Diamand, Jean-Baptiste Roche, Elena Lievore, et al.
The Prostate|October 19, 2022
Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsyMarco Oderda, Simone Albisinni, Daniel Benamran, et al.
Pageof 6